{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-085330","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2022-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.376838+00:00","generated_at":"2026-06-26T17:36:03.570535+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MindMed CFO David Guebert retiring Mar 31; director Vinson not seeking re-election; exec comp increases","bullets":["CFO David Guebert's last day is March 31, 2022; search for new CFO launched with executive search firm.","Director Sarah Y. Vinson will not stand for re-election at 2022 Annual Meeting; no disagreement cited.","Board reduces size from 6 to 5 effective at 2022 Annual Meeting.","CEO Robert Barrow base salary increased to $565,000, plus $233,411 cash bonus and equity awards.","Executive President Miri Halperin Wernli base salary raised to $390,000 with 40% target bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-085330","json":"https://secwatch.observer/filing/0001193125-22-085330.json","markdown":"https://secwatch.observer/filing/0001193125-22-085330.md","text":"https://secwatch.observer/filing/0001193125-22-085330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/0001193125-22-085330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/d314752d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T17:36:03.570535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae76d1a75b","claim":"David D. Guebert departed as Chief Financial Officer at Definium Therapeutics, Inc..","evidence_excerpt":"On March 25, 2022, David D. Guebert and the Company agreed to a separation from the Company with Mr. Guebert’s last day of employment on March 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/0001193125-22-085330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separation from the Company"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e231965e48","claim":"Sarah Y. Vinson departed as Director at Definium Therapeutics, Inc..","evidence_excerpt":"On March 24, 2022, Sarah Y. Vinson, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she will not stand for re-election as a director of the Company at its 2022 Annual Meeting","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312522085330/0001193125-22-085330-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}